BRASKEM SA-CLASS A- ADR (BAK) Stock Fundamental Analysis

NYSE:BAK • US1055321053

3.89 USD
0 (0%)
At close: Feb 20, 2026
3.92 USD
+0.03 (+0.77%)
After Hours: 2/20/2026, 8:18:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, BAK scores 2 out of 10 in our fundamental rating. BAK was compared to 83 industry peers in the Chemicals industry. BAK has a bad profitability rating. Also its financial health evaluation is rather negative. BAK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year BAK has reported negative net income.
  • In the past year BAK has reported a negative cash flow from operations.
  • BAK had negative earnings in 4 of the past 5 years.
  • BAK had a positive operating cash flow in 4 of the past 5 years.
BAK Yearly Net Income VS EBIT VS OCF VS FCFBAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B

1.2 Ratios

  • BAK has a Return On Assets of -6.36%. This is in the lower half of the industry: BAK underperforms 77.11% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 0.56%, BAK is doing worse than 75.90% of the companies in the same industry.
Industry RankSector Rank
ROA -6.36%
ROE N/A
ROIC 0.56%
ROA(3y)-5.51%
ROA(5y)-1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BAK Yearly ROA, ROE, ROICBAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

1.3 Margins

  • With a Operating Margin value of 0.60%, BAK is not doing good in the industry: 78.31% of the companies in the same industry are doing better.
  • BAK's Operating Margin has declined in the last couple of years.
  • BAK's Gross Margin of 6.52% is on the low side compared to the rest of the industry. BAK is outperformed by 87.95% of its industry peers.
  • In the last couple of years the Gross Margin of BAK has declined.
Industry RankSector Rank
OM 0.6%
PM (TTM) N/A
GM 6.52%
OM growth 3Y-60.34%
OM growth 5Y-26.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.57%
GM growth 5Y-9.41%
BAK Yearly Profit, Operating, Gross MarginsBAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BAK is destroying value.
  • The number of shares outstanding for BAK remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, BAK has about the same amount of shares outstanding.
  • Compared to 1 year ago, BAK has a worse debt to assets ratio.
BAK Yearly Shares OutstandingBAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
BAK Yearly Total Debt VS Total AssetsBAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • BAK has an Altman-Z score of 0.78. This is a bad value and indicates that BAK is not financially healthy and even has some risk of bankruptcy.
  • BAK has a worse Altman-Z score (0.78) than 78.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.78
ROIC/WACC0.1
WACC5.64%
BAK Yearly LT Debt VS Equity VS FCFBAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.21 indicates that BAK should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.21, BAK is doing worse than 86.75% of the companies in the same industry.
  • A Quick Ratio of 0.68 indicates that BAK may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.68, BAK is doing worse than 89.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.68
BAK Yearly Current Assets VS Current LiabilitesBAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • BAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.92%, which is quite impressive.
  • The Revenue has grown by 9.70% in the past year. This is quite good.
  • BAK shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.15% yearly.
EPS 1Y (TTM)26.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92%
Revenue 1Y (TTM)9.7%
Revenue growth 3Y-9.84%
Revenue growth 5Y8.15%
Sales Q2Q%-18.65%

3.2 Future

  • BAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.35% yearly.
  • BAK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.94% yearly.
EPS Next Y81.3%
EPS Next 2Y29.64%
EPS Next 3Y24.35%
EPS Next 5YN/A
Revenue Next Year-6.81%
Revenue Next 2Y0.23%
Revenue Next 3Y2.94%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BAK Yearly Revenue VS EstimatesBAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20B 40B 60B 80B 100B
BAK Yearly EPS VS EstimatesBAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 20 -20 40

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • BAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BAK Price Earnings VS Forward Price EarningsBAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • BAK's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.6
BAK Per share dataBAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • BAK's earnings are expected to grow with 24.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.64%
EPS Next 3Y24.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BAK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRASKEM SA-CLASS A- ADR

NYSE:BAK (2/20/2026, 8:18:06 PM)

After market: 3.92 +0.03 (+0.77%)

3.89

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-11
Earnings (Next)03-11
Inst Owners20.14%
Inst Owner Change-12.59%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.55B
Revenue(TTM)77.41B
Net Income(TTM)-5.81B
Analysts72.94
Price Target4.67 (20.05%)
Short Float %3.94%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-61.09%
DP-0.02%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.08%
Min EPS beat(2)64.59%
Max EPS beat(2)89.58%
EPS beat(4)2
Avg EPS beat(4)-292.98%
Min EPS beat(4)-870.87%
Max EPS beat(4)89.58%
EPS beat(8)2
Avg EPS beat(8)-200.87%
EPS beat(12)3
Avg EPS beat(12)-141.89%
EPS beat(16)4
Avg EPS beat(16)-120.57%
Revenue beat(2)0
Avg Revenue beat(2)-9.32%
Min Revenue beat(2)-10.48%
Max Revenue beat(2)-8.16%
Revenue beat(4)0
Avg Revenue beat(4)-6.86%
Min Revenue beat(4)-10.48%
Max Revenue beat(4)-1.01%
Revenue beat(8)0
Avg Revenue beat(8)-4.75%
Revenue beat(12)1
Avg Revenue beat(12)-3.68%
Revenue beat(16)2
Avg Revenue beat(16)-3.02%
PT rev (1m)0.21%
PT rev (3m)-6.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.77%
EPS NY rev (3m)14.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 13.6
EPS(TTM)-2.54
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-2.76
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS37.27
BVpS-1.82
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.36%
ROE N/A
ROCE 0.71%
ROIC 0.56%
ROICexc 0.56%
ROICexgc 0.59%
OM 0.6%
PM (TTM) N/A
GM 6.52%
FCFM N/A
ROA(3y)-5.51%
ROA(5y)-1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-67.54%
ROICexgc growth 5Y-28.26%
ROICexc growth 3Y-67.47%
ROICexc growth 5Y-28%
OM growth 3Y-60.34%
OM growth 5Y-26.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.57%
GM growth 5Y-9.41%
F-Score3
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 11.38
Cap/Depr 65.27%
Cap/Sales 4.08%
Interest Coverage 0.1
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.68
Altman-Z 0.78
F-Score3
WACC5.64%
ROIC/WACC0.1
Cap/Depr(3y)88.47%
Cap/Depr(5y)83.1%
Cap/Sales(3y)5.43%
Cap/Sales(5y)4.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92%
EPS Next Y81.3%
EPS Next 2Y29.64%
EPS Next 3Y24.35%
EPS Next 5YN/A
Revenue 1Y (TTM)9.7%
Revenue growth 3Y-9.84%
Revenue growth 5Y8.15%
Sales Q2Q%-18.65%
Revenue Next Year-6.81%
Revenue Next 2Y0.23%
Revenue Next 3Y2.94%
Revenue Next 5YN/A
EBIT growth 1Y374.38%
EBIT growth 3Y-64.24%
EBIT growth 5Y-20.05%
EBIT Next Year202.09%
EBIT Next 3Y93.22%
EBIT Next 5YN/A
FCF growth 1Y-736.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-158.55%
OCF growth 3Y-45.19%
OCF growth 5Y1.46%

BRASKEM SA-CLASS A- ADR / BAK FAQ

What is the ChartMill fundamental rating of BRASKEM SA-CLASS A- ADR (BAK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BAK.


Can you provide the valuation status for BRASKEM SA-CLASS A- ADR?

ChartMill assigns a valuation rating of 1 / 10 to BRASKEM SA-CLASS A- ADR (BAK). This can be considered as Overvalued.


What is the profitability of BAK stock?

BRASKEM SA-CLASS A- ADR (BAK) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BAK stock?

The Earnings per Share (EPS) of BRASKEM SA-CLASS A- ADR (BAK) is expected to grow by 81.3% in the next year.